Research

Employment Has Soared, But… the U.S. Federal Reserve Won’t Raise Interest Rates in September

iM Securities Report

kyoungeun kim
2026-09-07 07:40:11
[Edaily Reporter kyoungeun kim ] Despite August’s U.S. nonfarm payrolls figures significantly exceeding market expectations, forecasts indicate that the Federal Open Market Committee (FOMC) is still expected to keep interest rates unchanged at its September meeting.
U.S. President Trump (right) and Federal Reserve Chairman Kevin Warsh_[Reuters/Yonhap News file photo. Resale and database use prohibited]

Park Sang-hyun, an analyst at iM Securities, stated in a report on the 7th, “The surge in August’s nonfarm payrolls is a one-off phenomenon, and given the trend of slowing wage growth, it seems unlikely that August’s inflation data will trigger inflationary risks.”
Although nonfarm payrolls rose sharply in August, a closer look at the details raises questions about the sustainability of this trend. The analysis explains that the leisure sector and the government sector—which drove the job growth in August—had seen job losses or minimal gains in June and July, making it unclear whether this strong performance will continue into September. Given that the number of employed persons in the Household Survey—which is less volatile than nonfarm payrolls—declined for six of the seven months from January through July this year (excluding May), the sharp increase in August is likely to be merely a temporary phenomenon.
Wage growth rates were also highlighted as a key focus. In August, wages rose 0.3% month-over-month and 3.1% year-over-year, with the year-over-year wage growth rate continuing its trend of deceleration. It is explained that the slowdown in wage growth indicates the labor market is not as strong as the increase in the number of jobs suggests, while also serving as a factor that reduces inflationary pressure through the wage channel, which significantly influences service prices.
Political factors were also highlighted as significant. Immediately following the release of the employment data on the 4th, President Trump posted on the social media platform Truth Social: “A strong nation must have low interest rates. If interest rates are not lowered, the U.S. will cease trade with countries that run a deficit with us.” He added, “The Fed must become wise. It’s time to be patriotic.” Vice President J.D. Vance also publicly urged the Fed to cut interest rates, calling it an appropriate response to recent inflation data. Analysts suggest that, with the midterm elections approaching, President Trump is putting even more pressure on Chairman Kevin Warsh, as a September rate hike could negatively impact his re-election campaign.
Researcher Park said, “If Chairman Kevin Warsh is to go ahead with a September rate hike, it must be confirmed through data such as the consumer price index—to be released this week—that inflationary pressures are once again rising significantly.” He added, “However, based solely on current market forecasts for September’s consumer price index, it seems difficult to substantiate that inflationary pressures are spreading rapidly.”

Economy

Corporation

IT·Science

Economy

Shifting from Short-Term to Medium- and Long-Term... Appeal of Commercial Paper as a Funding Source Plummets

Fluctuations in credit spreads serve as an indicator of investor sentiment and capital flows in the corporate bond market. “Credit Signal” provides an intuitive analysis of the market’s overall trends…
2026-10-23 17:57:04

Corporation

SCL Science Takes on Liver and Ovarian Cancer Vaccines… Aims to File IND Application Next Year [Invest Bio]

SCL Science(246960)is accelerating its new drug development efforts, spearheaded by vaccines for liver and ovarian cancer. With the goal of submitting an Investigational New Drug (IND) application nex…
2026-10-24 06:01:03

IT·Science

HANALL BIOPHARMA CO.,LTD’s ‘Batoclimab’ Receives First New Drug Approval in China Nine Years After Technology Export

“Batoclimab,” a treatment for autoimmune diseases developed by HANALL BIOPHARMA CO.,LTD(009420), has received new drug approval in China. This comes approximately nine years after the company licensed…
2026-10-23 21:05:02